Carl Zeiss adds glaucoma data to StratusOCT:
This article was originally published in Clinica
Carl Zeiss Meditec has launched a new version of its retinal imaging instrument StratusOCT in Europe and Asia with an enhancement that can help improve glaucoma diagnosis. The latest device incorporates retinal fibre layer (RNFL) normative data, which provides clinicians with the normal ranges of retinal layer thickness, against which they can judge the measurements from their patients. This new version is currently awaiting FDA approval in the US. StratusOCT, an optical coherence tomographer, is the first instrument to provide cross-sectional imaging of the retina using ordinary light instead of X-rays, according to the Dublin, California firm. Glaucoma affects three million people in the US and is the leading cause of preventable blindness.
You may also be interested in...
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.